Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2

Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2

An Emergency Use Authorization was issued in the United States and in Europe for a monoclonal antibody monotherapy to prevent severe COVID-19 in high-risk patients. This study aimed to assess the risk of emergence of mutations following treatment with a single monoclonal antibody. Bamlanivimab was a...

Full description

Bibliographic Details
Main Authors: Nathan Peiffer-Smadja, Antoine Bridier-Nahmias, Valentine Marie Ferré, Charlotte Charpentier, Mathilde Garé, Christophe Rioux, Aude Allemand, Philippa Lavallée, Jade Ghosn, Laura Kramer, Diane Descamps, Yazdan Yazdanpanah, Benoit Visseaux
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Viruses
Subjects:
monoclonal antibodies
SARS-CoV-2
COVID-19
variants
resistance
Online Access:https://www.mdpi.com/1999-4915/13/8/1642

Internet

https://www.mdpi.com/1999-4915/13/8/1642

Similar Items